Current Approaches in Cancer Chemotherapy

Fatma İŞLİa , Gökçe Sevim ÖZTÜRK FİNCANb
aTurkish Medicines and Medical Devices Agency, Department of Rational Use of Medicines, Ankara, Türkiye
bGazi University Faculty of Medicine, Department of Medical Pharmacology, Ankara, Türkiye

İşli F, Öztürk Fincan GS. Current approaches in cancer chemotherapy. In: Yar Sağlam AS, ed. Innovative Approaches in Cancer Diagnosis and Treatment. 1st ed. Ankara: Türkiye Klinikleri; 2024. p.25-31.

Makale Dili: EN

ABSTRACT
Cancer incidence has been increasing gradually with fraught, probably due to changing way of life, rituals, and raised years of expected life. It is one of the top diseases of the 21st century causing fear and growing more prevalent. Just a limited number of treatments were available for cancer patients using for a long time, which may be called traditional therapy, including ”surgery, radiation therapy, and chemotherapy”, either alone or together. New approaches such as immunotherapy, stem cell therapy, hormonal therapy and gene therapy have provided satisfying results in cancer treatment. As these treatments improve and new ones are added, the cancer treatment has significantly contributed more effective results in terms of well-being and recovery of the patient. Thanks to advanced technologies, using recent cancer therapy alone or in combination with conventional therapy will make cancer a more manageable and treatable disease than before.

Keywords: Antineoplastic agents; drug therapy

Referanslar

  1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12-49. [Crossref]  [PubMed]
  2. Naser R, Dilabazian H, Bahr H, Barakat A, El-Sibai M. A guide through conventional and modern cancer treatment modalities: A specific focus on glioblastoma cancer therapy (Review). Oncol Rep. 2022;48(5):190. [Crossref]  [PubMed]
  3. Kaur R, Bhardwaj A, Gupta S. Cancer treatment therapies: traditional to modern approaches to combat cancers. Mol Biol Rep. 2023;50(11):9663-76. [Crossref]  [PubMed]
  4. Baykara O. Kanser Tedavisinde Güncel Yaklaşımlar. Balıkesir Sağlık Bilimleri Dergisi. 2016;5(3):154-65.
  5. Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2(2):141-60. [Crossref]  [PubMed]  [PMC]
  6. Pourquier P. Agents alkylants [Alkylating agents]. Bull Cancer. 2011;98(11):1237-51. French. [Crossref]  [PubMed]
  7. Bukowski K, Kciuk M, Kontek R. Mechanisms of Multidrug Resistance in Cancer Chemotherapy. Int J Mol Sci. 2020;21(9):3233. [Crossref]  [PubMed]  [PMC]
  8. McPartlin A, Grimaldo C, Lyons J, Burke D, Mitra S, Choudhury A. Successful delivery of chemotherapy to treat small-cell prostate cancer in a patient undergoing haemodialysis. Clin Kidney J. 2014;7(6):593-4. [Crossref]  [PubMed]  [PMC]
  9. Gupta T, Sinha S, Ghosh-Laskar S, Budrukkar A, Mummudi N, Swain M, et al. Intensity-modulated radiation therapy versus three-dimensional conformal radiotherapy in head and neck squamous cell carcinoma: long-term and mature outcomes of a prospective randomized trial. Radiat Oncol. 2020;15(1):218. [Crossref]  [PubMed]  [PMC]
  10. Kinhikar RA, Pawar AB, Mahantshetty U, Murthy V, Dheshpande DD, Shrivastava SK. Rapid Arc, helical tomotherapy, sliding window intensity modulated radiotherapy and three dimensional conformal radiation for localized prostate cancer: a dosimetric comparison. J Cancer Res Ther. 2014;10(3):575-82. [Crossref]  [PubMed]
  11. Chen H, Louie AV, Boldt RG, Rodrigues GB, Palma DA, Senan S. Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer: A Systematic Review. Clin Lung Cancer. 2016;17(5):e141-e9. [Crossref]  [PubMed]
  12. Takahashi K, Yamanaka S. Induced pluripotent stem cells in medicine and biology. Development. 2013;140(12):2457-61. [Crossref]  [PubMed]
  13. Chlebowski RT. Current concepts in breast cancer chemoprevention. Pol Arch Med Wewn. 2014;124(4):191-9. [Crossref]  [PubMed]
  14. Sakai M, Martinez-Arguelles DB, Patterson NH, Chaurand P, Papadopoulos V. In search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonist degarelix on human prostate cell growth. PLoS One. 2015;10(3):e0120670. [Crossref]  [PubMed]  [PMC]
  15. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol. 2009;10(10):981-91. [Crossref]  [PubMed]
  16. Groom AG, Younis T. Endocrine therapy for breast cancer prevention in high-risk women: clinical and economic considerations. Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):245-55. [Crossref]  [PubMed]
  17. Li F, Dou J, Wei L, Li S, Liu J. The selective estrogen receptor modulators in breast cancer prevention. Cancer Chemother Pharmacol. 2016;77(5):895-903. [Crossref]  [PubMed]
  18. Chlebowski RT, Manson JE, Anderson GL, Cauley JA, Aragaki AK, Stefanick ML, et al. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst. 2013;105(8):526-35. [Crossref]  [PubMed]  [PMC]
  19. Ohlmann CH. Chemotherapie des Prostatakarzinoms [Chemotherapy of prostate cancer]. Urologe A. 2015;54(10):1461-9; quiz 1470. German. [Crossref]  [PubMed]
  20. Müller P, Kreuzaler M, Khan T, Thommen DS, Martin K, Glatz K, et al. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci Transl Med. 2015;7(315):315ra188. [Crossref]
  21. Luo TY, Cheng PC, Chiang PF, Chuang TW, Yeh CH, Lin WJ. 188Re-HYNIC-trastuzumab enhances the effect of apoptosis induced by trastuzumab in HER2-overexpressing breast cancer cells. Ann Nucl Med. 2015;29(1):52-62. [Crossref]  [PubMed]
  22. Milling L, Zhang Y, Irvine DJ. Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev. 2017;114:79-101. [Crossref]  [PubMed]  [PMC]
  23. Agorastos T, Chatzistamatiou K, Katsamagkas T, Koliopoulos G, Daponte A, Constantinidis T, et al.; HERMES study group. Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology. PLoS One. 2015;10(3):e0119755. [Crossref]  [PubMed]  [PMC]
  24. Wei XX, Fong L, Small EJ. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions. Expert Rev Vaccines. 2015;14(12):1529-41. [Crossref]  [PubMed]
  25. Kulkarni GS. Nadofaragene firadenovec: a new gold standard for BCG-unresponsive bladder cancer? [published correction appears in Lancet Oncol. 2021;22(1):e5]. Lancet Oncol. 2021;22(1):8-9. [Crossref]  [PubMed]
  26. Ferrucci PF, Pala L, Conforti F, Cocorocchio E. Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. Cancers (Basel). 2021;13(6):1383. [Crossref]  [PubMed]  [PMC]
  27. Giordano P, Manzo A, Montanino A, Costanzo R, Sandomenico C, Piccirillo MC, et al. Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors. Crit Rev Oncol Hematol. 2016;97:143-51. [Crossref]  [PubMed]
  28. Thompson PA, Kantarjian HM, Cortes JE. Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015. Mayo Clin Proc. 2015;90(10):1440-54. [Crossref]  [PubMed]  [PMC]
  29. Burotto M, Manasanch EE, Wilkerson J, Fojo T. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. Oncologist. 2015;20(4):400-10. [Crossref]  [PubMed]  [PMC]
  30. Royce ME, Osman D. Everolimus in the Treatment of Metastatic Breast Cancer. Breast Cancer (Auckl). 2015;9:73-9. [Crossref]  [PubMed]  [PMC]
  31. Capozzi M, Caterina I, De Divitiis C, von Arx C, Maiolino P, Tatangelo F, et al. Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome it. Int J Surg. 2015;21 Suppl 1:S89-94. [Crossref]  [PubMed]
  32. Shah A, Mangaonkar A. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia. Ann Pharmacother. 2015;49(10):1162-70. [Crossref]  [PubMed]
  33. Teicher BA, Tomaszewski JE. Proteasome inhibitors. Biochem Pharmacol. 2015;96(1):1-9. [Crossref]  [PubMed]
  34. Iyer SP, Foss FF. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma. Oncologist. 2015;20(9):1084-91. [Crossref]  [PubMed]  [PMC]
  35. Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013;54(4):683-7. [Crossref]  [PubMed]  [PMC]
  36. Wirth T, Parker N, Ylä-Herttuala S. History of gene therapy. Gene. 2013;525(2):162-9. [Crossref]  [PubMed]
  37. Zhang J, Ding M, Xu K, Mao L, Zheng J. shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy. Oncotarget. 2016;7(20):29824-34. [Crossref]  [PubMed]  [PMC]
  38. Sun L, Zhang Q, Li Y, Tang N, Qiu X. CCL21/CCR7 up-regulate vascular endothelial growth factor-D expression via ERK pathway in human non-small cell lung cancer cells. Int J Clin Exp Pathol. 2015;8(12):15729-38.
  39. Kirchhoff F. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe. 2010;8(1):55-67. [Crossref]  [PubMed]
  40. Yu AM, Tu MJ. Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination. Pharmacol Ther. 2022;230:107967. [Crossref]  [PubMed]  [PMC]